Related Experiment Videos
Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed
Alejandro Perez1, John R Bartholomew
1Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Cleveland Clinic Journal of Medicine
|March 5, 2010
Summary
Statins may lower the risk of venous thromboembolism (VTE) in healthy individuals with elevated C-reactive protein. However, they are not a substitute for established VTE prevention methods.
Area of Science:
- Cardiovascular Medicine
- Preventive Cardiology
- Thrombosis Research
Background:
- Venous thromboembolism (VTE) poses a significant health risk.
- Identifying effective preventive strategies for VTE is crucial.
- The JUPITER trial investigated rosuvastatin's effects in a specific population.
Purpose of the Study:
- To analyze a secondary endpoint of the JUPITER trial.
- To evaluate the effect of statin therapy on venous thromboembolism (VTE) risk.
Main Methods:
- Secondary endpoint analysis of the JUPITER trial data.
- Inclusion of apparently healthy individuals with high C-reactive protein and normal LDL cholesterol.
Main Results:
- Statin use was associated with a reduced risk of venous thromboembolism (VTE).
- This finding was observed in individuals with high C-reactive protein and normal low-density lipoprotein cholesterol.
Conclusions:
- Statins may offer a potential benefit in VTE prevention for select individuals.
- Further research is needed before statins can replace standard VTE prophylaxis and anticoagulation.
- Current guidelines for VTE prevention should be maintained, especially for high-risk patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...